Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.32 |
| ▸ | CCR5 | P51681 | 3/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835457 | 0.96 | OPRM1 (0.32) | OPRM1OPRL1FPR2PROKR1BDKRB1 | |
| SCHEMBL2834819 | 0.88 | OPRM1 (0.31) | OPRM1OPRL1CCR5TACR2TACR1 | |
| SCHEMBL2833740 | 0.86 | BDKRB1 (0.33) | OPRM1OPRL1FPR2PROKR1BDKRB1 | |
| SCHEMBL2835461 | 0.85 | BDKRB1 (0.34) | OPRM1OPRL1FPR2PROKR1BDKRB1 | |
| SCHEMBL2833737 | 0.85 | OPRM1 (0.32) | OPRM1OPRL1FPR2PROKR1BDKRB1 | |
| SCHEMBL2833659 | 0.84 | HTR7 (0.35) | OPRM1OPRL1 | |
| SCHEMBL2835307 | 0.84 | OPRM1 (0.31) | OPRM1OPRL1BDKRB1 | |
| SCHEMBL2835458 | 0.84 | OPRM1 (0.33) | OPRM1OPRL1BDKRB1 | |
| SCHEMBL2832177 | 0.83 | TSHR (0.32) | — | |
| SCHEMBL2834659 | 0.82 | OPRM1 (0.32) | OPRM1OPRL1CCR5BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | claimed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | claimed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | claimed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | ADORA2B, CCNB1, TYMS | OPRM1 1056/4885OPRL1 522/4885CCR5 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.